HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prophylactic hepatic artery infusion chemotherapy improved survival after curative resection in patients with hepatocellular carcinoma.

AbstractBACKGROUND/AIMS:
To explore the effect of prophylactic hepatic artery infusion chemotherapy (HAIC) on survival probability after curative resection in patients with hepatocellular carcinoma (HCC).
METHODOLOGY:
85 patients with HCC were randomly assigned to HAIC group (42 cases) and control group (43 patients), all the database of two groups had no significant difference. Patients in HAIC groups underwent hepatic artery infusion chemotherapy (5-FU 1000 mg/m2 on day 1, Oxaliplatin 85 mg/m2 on day 1 and Gemcitabine 1000 mg/m2 on day 1 and 8) starting 3 weeks after operation with intervals of 4 weeks. All patients were followed up for 3 years and intrahepatic recurrence-free survival, disease-free survival rate and overall survival rate were recorded.
RESULTS:
Intrahepatic recurrence rate of HAIC group and the control group was respectively 19.05% and 39.53%, P < 0.05. Disease-free survival rate was respectively 57.14% and 44.19%, P < 0.05. Overall survival rate was 66.67% and 46.51%, P < 0.05. All patients in HAIC group tolerated the therapy. No adverse effect above grade 3 was reported in HAIC group.
CONCLUSION:
HAIC effectively and safely prevents intrahepatic recurrence and improves the prognosis of patients with HCC after curative resection.
AuthorsSan Xiong Huang, Yu Lian Wu, Cheng Wu Tang, Wen Ming Feng, Yong Qiang Xu, Ying Bao, Yin Yuan Zheng
JournalHepato-gastroenterology (Hepatogastroenterology) 2015 Jan-Feb Vol. 62 Issue 137 Pg. 122-5 ISSN: 0172-6390 [Print] Greece
PMID25911881 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Organoplatinum Compounds
  • Oxaliplatin
  • Deoxycytidine
  • Gemcitabine
Topics
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Carcinoma, Hepatocellular (mortality, pathology, therapy)
  • Chemotherapy, Adjuvant
  • China
  • Deoxycytidine (administration & dosage, analogs & derivatives)
  • Disease Progression
  • Disease-Free Survival
  • Drug Administration Schedule
  • Female
  • Hepatectomy (adverse effects, mortality)
  • Hepatic Artery
  • Humans
  • Infusions, Intra-Arterial
  • Kaplan-Meier Estimate
  • Liver Neoplasms (mortality, pathology, therapy)
  • Male
  • Middle Aged
  • Neoadjuvant Therapy (adverse effects, mortality)
  • Neoplasm Recurrence, Local
  • Organoplatinum Compounds (administration & dosage)
  • Oxaliplatin
  • Prospective Studies
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: